Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system.

Kanmura S, Uto H, Kusumoto K, Ishida Y, Hasuike S, Nagata K, Hayashi K, Ido A, Stuver SO, Tsubouchi H.

Hepatology. 2007 Apr;45(4):948-56.

PMID:
17393466
2.

Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.

Wu C, Wang Z, Liu L, Zhao P, Wang W, Yao D, Shi B, Lu J, Liao P, Yang Y, Zhu L.

J Gastroenterol Hepatol. 2009 Jan;24(1):55-62. doi: 10.1111/j.1440-1746.2008.05580.x. Epub 2008 Sep 24.

PMID:
18823443
3.

SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.

Geng X, Wang F, Li YG, Zhu GP, Zhang WM.

J Exp Clin Cancer Res. 2007 Dec;26(4):505-8.

PMID:
18365545
4.

Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification.

Cui J, Kang X, Dai Z, Huang C, Zhou H, Guo K, Li Y, Zhang Y, Sun R, Chen J, Li Y, Tang Z, Uemura T, Liu Y.

J Cancer Res Clin Oncol. 2007 Nov;133(11):825-34. Epub 2007 May 22.

PMID:
17516088
5.

Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma.

He QY, Zhu R, Lei T, Ng MY, Luk JM, Sham P, Lau GK, Chiu JF.

J Cell Biochem. 2008 Feb 15;103(3):740-52.

PMID:
17557278
6.

Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.

Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, Afdhal NH.

Clin Cancer Res. 2008 Jan 15;14(2):470-7. doi: 10.1158/1078-0432.CCR-07-0586.

7.

Identification of beta2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis.

Saito Y, Oba N, Nishinakagawa S, Mizuguchi Y, Kojima T, Nomura K, Nakatsura T.

Oncol Rep. 2010 May;23(5):1325-30.

PMID:
20372847
8.

Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases.

Paradis V, Degos F, Dargère D, Pham N, Belghiti J, Degott C, Janeau JL, Bezeaud A, Delforge D, Cubizolles M, Laurendeau I, Bedossa P.

Hepatology. 2005 Jan;41(1):40-7.

PMID:
15690480
9.

Application of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry coupled with an artificial neural network model for the diagnosis of hepatocellular carcinoma.

Hu Q, Huang Y, Wang Z, Tao H, Liu J, Yan L, Wang K.

Hepatogastroenterology. 2012 Sep;59(118):1902-6. doi: 10.5754/hge11771.

PMID:
22193438
10.

Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma.

Wang JX, Zhang B, Yu JK, Liu J, Yang MQ, Zheng S.

Chin Med J (Engl). 2005 Aug 5;118(15):1278-84.

PMID:
16117882
11.

Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy.

Wu FX, Wang Q, Zhang ZM, Huang S, Yuan WP, Liu JY, Ban KC, Zhao YN.

Cancer Lett. 2009 Jul 8;279(2):163-70. doi: 10.1016/j.canlet.2009.01.034. Epub 2009 Mar 5.

PMID:
19268439
12.

Serum profiling based on fucosylated glycoproteins for differentiating between chronic hepatitis B and hepatocellular carcinoma.

Liao J, Zhang R, Qian H, Cao L, Zhang Y, Xu W, Li J, Wu M, Yin Z.

Biochem Biophys Res Commun. 2012 Apr 6;420(2):308-14. doi: 10.1016/j.bbrc.2012.02.155. Epub 2012 Mar 7.

PMID:
22425980
13.

Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker.

Chen L, Ho DW, Lee NP, Sun S, Lam B, Wong KF, Yi X, Lau GK, Ng EW, Poon TC, Lai PB, Cai Z, Peng J, Leng X, Poon RT, Luk JM.

Ann Surg Oncol. 2010 Sep;17(9):2518-25. doi: 10.1245/s10434-010-1038-8. Epub 2010 Mar 31.

14.

Predicting early intrahepatic recurrence of hepatocellular carcinoma after microwave ablation using SELDI-TOF proteomic signature.

Cao XL, Li H, Yu XL, Liang P, Dong BW, Fan J, Li M, Liu FY.

PLoS One. 2013 Dec 13;8(12):e82448. doi: 10.1371/journal.pone.0082448. eCollection 2013.

15.

The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma.

Kanmura S, Uto H, Sato Y, Kumagai K, Sasaki F, Moriuchi A, Oketani M, Ido A, Nagata K, Hayashi K, Stuver SO, Tsubouchi H.

J Gastroenterol. 2010 Apr;45(4):459-67. doi: 10.1007/s00535-009-0160-5. Epub 2009 Dec 9.

PMID:
20012107
16.

Application of serum SELDI proteomic patterns in diagnosis of lung cancer.

Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, Zhou B, Chen G, He DC.

BMC Cancer. 2005 Jul 20;5:83.

17.

MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of hepatocellular carcinoma.

Liu C, Shen J, Pan C, Yang L, Mou S, Wang H, Liang Y.

Am J Clin Pathol. 2010 Aug;134(2):235-41. doi: 10.1309/AJCPA6C6NOGFLYIR.

PMID:
20660326
18.

Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis.

Ward DG, Cheng Y, N'Kontchou G, Thar TT, Barget N, Wei W, Billingham LJ, Martin A, Beaugrand M, Johnson PJ.

Br J Cancer. 2006 Jan 30;94(2):287-92.

19.

New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples.

Göbel T, Vorderwülbecke S, Hauck K, Fey H, Häussinger D, Erhardt A.

World J Gastroenterol. 2006 Dec 21;12(47):7604-12.

20.

Supplemental Content

Support Center